This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-14. Anything still debated is marked as such rather than presented as settled.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Smoking or vaporizing: Using these methods, rather than injecting, is thought to reduce the risk of infections, since the high temperatures involved are more likely to kill bacteria and spores. Grinding into a powder form for snorting: This is one of the more popular ways of consuming black tar for those who do not wish to use needles. The black tar heroin is put into some sort of blender and mixed in with lactose. This creates a fine black powder product that can be easily snorted. Water looping: Water looping is when a user places the heroin in an empty eye dropper bottle, or a syringe with the needle removed. The user allows the heroin to completely dissolve into water and the solution is dropped into the nose. This at times can be wasteful if a user allows too much of the solution to go down the throat. Drinking: This is done similar to the water looping method. Instead of being delivered through the nose, the solution is swallowed. Suppository: The most effective route of administration which does not require a needle, is accomplished by delivering a solution (via syringe) or lubricated mass of the narcotic deep into the rectum or vagina.
On 3 April, Ruthaphon Naowarat, Minister of Justice, stated in CCSA Press Conference that the Ministry of Justice had detected 57 million litres of fuel missing from 217 million litres transported by sea to six oil depots in Surat Thani province, only 160 million litres arrived at destination. This has created controversies regarding government responsibilities. On 4 April, Bangchak Corporation, the third largest oil company in Thailand with around 2200 petrol stations nationwide, announced the "Fry to Fly" Program, which offers customers to exchange 2 litres of used cooking oil for 1 litre of diesel fuel or petrol (up to 20 litres of cooking oil per person) at 15 stations across the Bangkok Metropolitan Region. This program reduces customers' fuel costs and allows Bangchak to use the used cooking oil to produce sustainable aviation fuel (SAF). The program will be in effect from 6 to 30 April. On 8 April, the Energy Policy Administration Committee announced on the Royal Gazette of Thailand that diesel prices would be cut at the refinery level by 2 THB per litre, aiming to reduce fuel costs and cost of living for Thai citizens. This reduction includes Diesel B0, Diesel B7 and Diesel B20 blends, effective from 9 April. This resulted in diesel fuel prices dropping from 50.54 THB per litre on 7 April, to 48.40 THB per litre on 9 April. On 11 April prices dropped to 44.40 THB per litre for normal diesel and to 37.40 THB per litre for Diesel B20.
== Treatment == Traditionally, nothing by mouth was considered to be mandatory in all cases, but gentle feeding by enteral feeding tube may help to restore motility by triggering the gut's normal feedback signals, so this is the recommended management initially. When the patient has severe, persistent signs that motility is completely disrupted, nasogastric suction and parenteral nutrition may be required until passage is restored. In such cases, continuing aggressive enteral feeding causes a risk of perforating the gut. Several options are available in the case of paralytic ileus. Most treatment is supportive. If caused by medication, the offending agent is discontinued or reduced. Bowel movements may be stimulated by prescribing lactulose, erythromycin or, in severe cases that are thought to have a neurological component (such as Ogilvie's syndrome), neostigmine. There is also evidence from a systematic review of randomized controlled trials that chewing gum, as a form of 'sham feeding', may stimulate gastrointestinal motility in the post-operative period and reduce the duration of postoperative ileus. If possible, the underlying cause is corrected (e.g. replace electrolytes).
Sources: en.wikipedia.org
In response to an injury, infection, or other immune response, the spindle cells of connective tissue will begin dividing to heal the affected area; if the tissue is predisposed to spindle cell cancer, the high cellular turnover may result in a cell mutating, becoming cancerous, and forming a tumor.
==== Silica ==== Silica is a contaminant that is detrimental to microelectronics processing and must be maintained at sub-ppb levels. In steam power generation silica can form deposits on heat-exchange surfaces where it reduces thermal efficiency. In high temperature boilers, silica will volatilize and carry over with steam where it can form deposits on turbine blades which lower aerodynamic efficiency. Total silica can be measured using atomic emission spectroscopy or mass spectrometry, while dissolved silica can be detected using colorimetric methods. In the colorimetric method, reagents including molybdate are added to solution which creates a blue silico-molybdate complex that can be detected using UV-Vis spectroscopy.
=== Human food supply outside of U.S. === On 7 June 2007, the European Food Safety Authority (EFSA) issued a provisional statement, noting that they were investigation potential synergistic effects between melamine and cyanuric acid. However, by 21 June, the Health & Consumer Protection Directorate-General of the European Commission found that there was "no need to take restrictive measures" on livestock who had eaten contaminated feed, nor on food products derived from such animals. In 2008, the reports of contaminated powdered milk in China led to renewed examination of potential health risks. The EFSA issued a press release on 25 September 2008, noting that children who consumed above-average levels of milk products could potentially be at risk. A report from the Chinese Ministry of Health found that 294,000 infants in China had been affected by melamine-contaminated infant formula by the end of November 2008. More than 50,000 infants were hospitalized, and six deaths were confirmed, as a result of this contamination.
=== Papillitis/hypertrophy === Papillitis refers to inflammation of the papillae, and sometimes the term hypertrophy is used interchangeably. In foliate papillitis the foliate papillae appear swollen. This may occur due to mechanical irritation, or as a reaction to an upper respiratory tract infection. Other sources state that foliate papilitis refers to inflammation of the lingual tonsil, which is lymphoid tissue.
Sources: en.wikipedia.org
It is recommended for mothers to initiate breastfeeding within the first hour after birth. Uninterrupted skin-to-skin contact and breastfeeding can begin immediately after birth, and should continue for at least one hour after birth. This period of infant-mother interaction, known generally as kangaroo care, or the "golden hour" during the immediate postpartum period, assists in the mother–child bonding for both mother and baby, and is thought to encourage instinctual breastfeeding behavior in the infant. Newborns who are immediately placed on their mother's skin have a natural instinct to latch on to the breast and start nursing, typically within one hour of birth. Success with breastfeeding in this "golden hour" increases the likelihood of successful breastfeeding at discharge. Skin-to-skin mother-baby contact should still occur, even if the baby is born by Cesarean section. The baby is placed on the mother in the operating room or the recovery area. If the mother is unable to immediately hold the baby, a family member can provide skin-to-skin care until the mother is able.
== Overdose == Symptoms of acute and acute on chronic exposure to topiramate range from asymptomatic to status epilepticus, including in patients with no seizure history. In children, overdose may also result in hallucinations. Topiramate has been deemed the primary substance that led to fatal overdoses in cases that were complicated by polydrug exposure. The most common signs of overdose are dilated pupils, somnolence, dizziness, psychomotor agitation, and abnormal, uncoordinated body movements.
=== Taxes === During his 2022 gubernatorial campaign, Moore repeatedly said that he did not anticipate raising taxes as governor, but said in September 2022 that he planned to work with the legislature to fix what he described as the state's "upside-down taxation system". In January 2024, he expressed openness to raising taxes to address the state's budget shortfall, but said that any conversation about taxes would have a "very high bar". That year, the legislature amended Moore's budget proposal, which included no tax increases, to add about $252 million in increases toward transportation-related fees and tobacco taxes to help pay for the Blueprint for Maryland's Future reforms and state transportation projects. In May 2022, following a spike in gas prices as a result of the Russo-Ukrainian War, Moore said he supported staving off automatic increases to the state's gas tax, arguing that voters needed immediate relief and later calling it a "regressive tax". He also expressed interest in eliminating either the state's estate or inheritance tax to make the state more attractive to retirees. In June 2023, Moore said he supported shifting transportation funding away from the state's gas tax as well as decoupling it from inflation, but opposed calling a special session to do so, instead preferring to pass tax reforms during the 2024 legislative session. In March 2026, Moore opposed a Republican proposal to implement a 30-day gas tax holiday following a spike in gas prices as a result of the 2026 Iran war.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.